Legend Biotech✓

New research from our LB2102 program is being presented at #ESMO2026, highlighting our ongoing work to explore the potential of cell therapy in solid tumors. #CellTherapy #CART #ESMO26

Scientific progress rarely begins with certainty. It begins with the willingness to keep exploring.​ At Legend Biotech, our research is driven by a deeper understanding of cell biology and a commitment to exploring new approaches that could help shape the future of cell therapy.​ By continuing to learn from the science, we’re working to uncover new possibilities for patients.​ #LegendBiotech #CellTherapy #Biotech #Innovation

We’re continuing to advance our pipeline and explore new approaches in cell therapy. The U.S. FDA has cleared the IND application for LB2501, marking an important step for our in vivo cell engineering platform and enabling planned U.S. clinical development. Learn more: #CellTherapy #CART

What if cell therapies could be created directly inside the body?​ That's the promise of in vivo cell therapy. By delivering genetic instructions directly to immune cells, researchers are exploring approaches that could simplify treatment and expand future possibilities.​ #CellTherapy #Oncology

Applications are now open for Legend Biotech’s inaugural ELITE Program (Emerging Leadership & Innovation in Cell Therapy Excellence). The annual grant initiative is designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma. Through the ELITE Program, we’re investing in the next generation of innovators and the ideas that can help advance research, education, and care for patients living with multiple myeloma. Applications are open through November 20, 2026. Learn more and apply:

A milestone moment at #IMS2026: Today, Adam D. Cohen, MD, presented 5-year CARTITUDE-2 Cohort A findings, contributing new insights into long-term RRMM patient outcomes following earlier-line treatment. Explore the key findings: #LegendBiotech #MultipleMyeloma #CellTherapy #CART

5-year CARTITUDE-2 Cohort A data at #IMS2026 We presented long-term findings from CARTITUDE-2 Cohort A in patients with relapsed or refractory multiple myeloma (RRMM) treated as early as second line. Learn more: #LegendBiotech #MultipleMyeloma #CellTherapy #CART

Real-world evidence is deepening our understanding of CAR-T cell therapy. Initial findings presented today at IMS from our PASS study broaden our understanding of earlier treatment and patient outcomes. Stop by PA-199 to explore the findings and learn more. #LegendBiotech #CART #MultipleMyeloma

We’re heading to Glasgow for #IMS2026! Sept. 23–26, Legend will share new and updated data, including long-term findings from the CARTITUDE clinical development program and real-world evidence advancing our understanding of CAR-T cell therapy in multiple myeloma. Visit us at Booth #1453. #LegendBiotech #MultipleMyeloma #CellTherapy #CART

That’s a wrap on #SOHO2026. The meeting brought the hematologic oncology community together in Houston to exchange the latest research shaping the field. At #SOHO2026, Legend Biotech shared encore #CARTITUDE4 subgroup data adding to the growing body of evidence on how disease control before CAR-T infusion may relate to longer-term outcomes. These insights help deepen our understanding of the CAR-T treatment journey and reinforce our commitment to advancing cell therapy with patients at the center. We’re proud to work alongside the scientific community advancing this important work. #LegendBiotech #CellTherapy #Oncology #Hematology

Today, we announced the appointment of Ingrid Zhang as Chief Executive Officer of Legend Biotech. An accomplished global biopharmaceutical executive, Ingrid joins Legend as we continue building on our strong foundation, advancing our pipeline and working to transform outcomes for patients through cell therapy. Read more: #LegendBiotech #CellTherapy

For our team, being at @SocietyofHemOnc is about more than attending a conference. It’s an opportunity to listen, learn, and connect with the physicians and care teams working with patients every day. The insights gained through these conversations help shape how we support the field and continue advancing cell therapy for patients. Meet some of the people representing Legend on the ground in Houston. #LegendBiotech #CellTherapy #Oncology #SOHO2026

As the CAR-TCR Summit comes to a close in Boston, we’re reflecting on the conversations shaping the future of advanced cell therapy.​ ​During a panel discussion, Legend Biotech’s Emad Abdelnaby joined industry leaders to explore what it takes to successfully bring cell therapies from development to commercialization, from scaling and patient access to manufacturing, regulatory planning and reimbursement.​ ​Thank you to everyone who joined the conversation.​ ​#LegendBiotech #CellTherapy #Biotech

Live from #SOHO2026 #CARTITUDE4 data are helping deepen our understanding of disease control before CAR-T infusion, including response to bridging therapy. The key takeaway? Greater insight into the role of bridging therapy in patients with standard-risk and high-risk cytogenetics. Here at #SOHO2026? Stop by Booth #125 to connect with the Legend Biotech team and learn more. #LegendBiotech #CellTherapy

New data is coming at #IMS26. At the 23rd International @Myeloma_Society Annual Meeting in Glasgow, Legend Biotech will present data from our CAR-T cell therapy, including long-term, post-authorization and real-world findings. These insights build on learnings from our clinical program as we continue our focus on advancing scientific innovation and reaching patients globally. Learn more about the data we’ll be sharing in Glasgow: #LegendBiotech #CellTherapy #ClinicalResearch

We’re here! @SOHO 2026 is officially underway in Houston, TX, and the Legend Biotech team is on the ground. We’re looking forward to connecting with colleagues, exchanging insights, and being part of the conversations advancing the future of multiple myeloma and cell therapy. Visit us at Booth #125 and follow along for more from #SOHO2026. #LegendBiotech #CellTherapy

Next week, Legend Biotech is heading to Houston for the @SocietyofHemOnc Annual Meeting. Visit us at booth #125 throughout the conference. We look forward to joining the hematologic oncology community to discuss the latest scientific discussions and research. Don’t miss our poster presentation featuring the CARTITUDE-4 Cytogenetic subgroup analysis. Stay tuned for more from #SOHO2026. #LegendBiotech #CellTherapy #Oncology

CAR-T is changing how researchers think about harnessing the immune system to fight cancer.​ ​At the center of this approach are T cells and the ability to modify them to recognize specific targets on cancer cells. As research continues to advance, understanding the science behind CAR-T can help build greater awareness of how cell therapy is evolving.​ ​#CellTherapy #CancerResearch #Biotech #PatientsFirst

September marks Blood Cancer Awareness Month, a time to recognize the patients, caregivers, healthcare professionals, researchers, and advocates helping advance progress against blood cancers. ​Throughout the month, we'll highlight scientific advancements, key oncology meetings, and ongoing efforts supporting blood cancer research and cell therapy. ​#BloodCancerAwarenessMonth #CellTherapy #CancerResearch #Oncology